title: [Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma].
abstract: OBJECTIVE
  To investigate the clinical efficacy and safety between CHOPE regimen alone and it combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma.
  
  
  METHODS
  Eighty patients with relapsed and refractory non-Hodgkin's B cell lymphoma were chosen in our hospital from January 2009 to June 2012, and randomly were divided into 2 groups including the CHOPE regimen group (40 patients) and CHOPE plus thalidomide group (40 patients); and the clinical efficacy, the levels of sVEGF and LDH before and after treatment, the survival rate and the III-IV degree toxic side-effects in these 2 groups were compared.
  
  
  RESULTS
  The clinical efficacy of CHOPE+thalidomide group was significant higher than that of CHOPE group alone (P < 0.05). The levels of sVEGF and LDH after treatment in the CHOPE+thalidomide group was significantly higher than that in CHOPE group alone before treatment (P < 0.05). The survival rate in CHOPE+thalidomide group was significant higher than that in CHOPE group alone (P < 0.05). The median survival time in CHOPE+thalidomide group was significant longer than that in CHOPE group alone (P < 0.05). The incidence of III-IV degree toxic side effects was not significantly different between 2 these groups (P > 0.05).
  
  
  CONCLUSIONS
  Compared with CHOPE regimen alone, CHOPE regimen combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma can efficiently delay the disease progression, reduce tumor burden level, enhance the long-term survival rate, morever did not increase the risk of toxic side effects.
authors.affiliation: Department of Oncology, Dianjiang Country Hospital of Traditional Chinese Medicine, Chongqing 408300. E-mail: 927501170@qq.com.
authors.forename: Ying-Zi
authors.initials: YZ
authors.lastname: Yang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D045022:Lactate Dehydrogenases / Q000378:metabolism; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local; D011241:Prednisone / Q000627:therapeutic use; D015996:Survival Rate; D013792:Thalidomide / Q000627:therapeutic use*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000097:blood; D014750:Vincristine / Q000627:therapeutic use
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D013792:Thalidomide; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D045022:Lactate Dehydrogenases; D011241:Prednisone